Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

Autifony Therapeutics Ltd.. (8/26/20). "Press Release: Autifony Therapeutics Regains Rights to Clinical Stage Kv3 Programme". Stevenage.

Organisations Organisation Autifony Therapeutics Ltd.
  Group Autifony (Group)
  Organisation 2 Boehringer Ingelheim (Group)
Products Product AUT00206 (Autifony Therapeutics)
  Product 2 AUT00201 (Autifony Therapeutics)
Index term Index term Boehringer–Autifony: CNS drugs, 201712–202008 collab €25m upfront + €627.5m milestones excl option to KV3.1/3.2 modulators for BI TERMINATED 8/20
Persons Person Large, Charles (Autifony 201712 CEO before CSO)
  Person 2 Zaccagnini, Kiki (Instinctif Partners 202007)
     


Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious nervous system disorders, including hearing disorders and schizophrenia, today announced that Autifony has regained full rights to its Kv3 programme. Boehringer Ingelheim will not be exercising its Option under the Option for Asset Purchase Agreement which was signed by the two companies in December 2017. Boehringer Ingelheim’s decision is for strategic reasons and the Agreement between the companies has now ended.

Under the Agreement, Autifony received a €25 million upfront payment, followed by €17.5 million in milestone payments during the Option period. The Kv3 programme progressed significantly during the collaboration with BI, obtaining positive data in a ketamine challenge clinical trial in healthy volunteers, in which the lead molecule, AUT00206, demonstrated clear central nervous system target engagement. During the Option period, Autifony also successfully completed a safety study with AUT00206 in patients with schizophrenia, which generated biomarker data supportive of further progression for this indication. During the last few months Autifony has progressed a further Kv3 molecule, AUT00201, into Phase I, and additional molecules are well advanced for other indications.

Dr Charles Large, Chief Executive Officer of Autifony Therapeutics, commented: “We have very much enjoyed working with Boehringer Ingelheim over the last three years. The collaboration has enabled Autifony to progress the Kv3 programme, completing Phase I and generating a substantial body of data that supports the potential of this novel mechanism for the treatment of schizophrenia and hearing loss.

“Furthermore, we have been able to bring forward additional clinical and development candidate stage Kv3 modulators that can be explored across a broader range of indications, including Fragile X and chronic pain. We are excited about the extraordinary opportunity that the Kv3 programme offers and look forward to progressing our first-in-class compounds into the next phase of development.”


About Autifony Therapeutics Ltd

Autifony Therapeutics is an independent UK based biotechnology company formed in 2011 as a spin-out from GSK, which retains equity in the company. The Company is focused on the development of high value, novel medicines to treat hearing disorders and other serious diseases of the central nervous system. It is funded by SV Health Investors, IP Group, Pfizer Ventures, International Biotechnology Trust PLC, and UCL Business plc.


For more information, please contact:

Autifony Therapeutics Limited
Dr Charles Large, CEO
E: Charles.Large@autifony.com

Instinctif Partners
Tim Watson / Kiki Zaccagnini
T: +44 (0) 20 7866 7861
E: Autifony@instinctif.com

   
Record changed: 2020-08-30

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Autifony (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81




» top